VX-765: Selective Caspase-1 Inhibitor for Inflammation & Pyroptosis Research

Executive Summary: VX-765 is a prodrug that is metabolized to VRT-043198, a potent inhibitor of caspase-1 (ICE), and also exhibits moderate inhibition of caspase-8 (IC₅₀ = 1 μM) (Bourne et al., 2025). VX-765 selectively reduces IL-1β and IL-18 secretion without broadly suppressing other cytokines. It enables targeted modulation of the canonical inflammasome pathway in preclinical models of arthritis, skin inflammation, and HIV-associated CD4 T-cell death (ApexBio VX-765). The compound is orally bioavailable, soluble in DMSO (≥313 mg/mL) and ethanol (≥50.5 mg/mL with ultrasonic), but insoluble in water. VX-765 is under investigation for translational applications in epilepsy and inflammatory diseases, with robust data supporting its use in dissecting caspase-1-driven pyroptosis (see related article).

Biological Rationale

Caspases are cysteine proteases that regulate programmed cell death and inflammation. Caspase-1, also called interleukin-1 converting enzyme (ICE), is the primary mediator of canonical inflammasome signaling in response to pathogen- or damage-associated molecular patterns (PAMPs, DAMPs) (Bourne et al., 2025). Upon activation, caspase-1 cleaves pro-IL-1β and pro-IL-18, generating their active, secreted forms that drive acute and chronic inflammation. Caspase-1 also cleaves gasdermin D (GSDMD), promoting pyroptosis—a lytic, inflammatory cell death pathway especially relevant in macrophages during infection. Unlike apoptotic caspases, inflammatory caspases (caspase-1, -4, -5 in humans) act as both initiators and executioners of cell death. Targeted inhibition of caspase-1 allows precise control of IL-1β and IL-18 release, providing a mechanistic tool to dissect cytokine-driven disease processes. VX-765, by selectively inhibiting caspase-1, enables researchers to delineate the contribution of the inflammasome pathway without global immune suppression.

Mechanism of Action of VX-765

VX-765 is an orally absorbed prodrug. In vivo, it is rapidly converted to its active metabolite, VRT-043198, which binds to the active site of caspase-1 and blocks its proteolytic activity (Bourne et al., 2025). This inhibition prevents the cleavage of pro-IL-1β and pro-IL-18, thereby reducing their secretion. VX-765 does not significantly affect the secretion of other cytokines such as IL-6, IL-8, TNFα, or IL-α, which distinguishes it from broad-spectrum anti-inflammatory drugs. Notably, VX-765 also exhibits moderate inhibition of caspase-8 at higher concentrations (IC₅₀ = 1 μM), but its primary effect is on caspase-1 under standard assay conditions (pH 7.5, buffered, with enzyme stabilizers) (Table 1). This selectivity profile makes VX-765 a valuable tool for distinguishing canonical inflammasome-mediated events from other cell death or signaling pathways.

Evidence & Benchmarks

• VX-765 inhibits human caspase-1 with high potency in vitro; active metabolite VRT-043198 directly blocks caspase-1 activity (Bourne et al., 2025, DOI).
• VX-765 reduces secretion of IL-1β and IL-18 without affecting IL-6, IL-8, TNFα, or IL-α in cell-based assays (ApexBio datasheet, link).
• In collagen-induced arthritis mouse models, VX-765 significantly lowers joint inflammation and cytokine levels (ApexBio datasheet, link).
• VX-765 prevents CD4 T-cell pyroptotic death in ex vivo HIV-infected human lymphoid tissues in a dose-dependent manner (ApexBio datasheet, link).
• Biochemical assays confirm VX-765 has an IC₅₀ of ~1 μM for caspase-8, indicating moderate off-target inhibition at elevated concentrations (Bourne et al., 2025, DOI).

For an advanced comparison of VX-765 with other caspase inhibitors in cellular and biochemical settings, see 'Harnessing Selective Caspase-1 Inhibition', which provides a broader mechanistic context. This article further clarifies VX-765's unique selectivity profile by integrating new comparative data.

Applications, Limits & Misconceptions

VX-765 is widely used in research targeting inflammasome-driven inflammation, rheumatoid arthritis, skin inflammation, and HIV-associated pyroptosis. Its selectivity enables precise dissection of canonical inflammasome pathways, making it valuable for both mechanistic studies and translational models. VX-765's oral bioavailability and metabolic activation profile support its use in animal studies and ex vivo human tissue systems. However, its moderate off-target activity against caspase-8 requires careful interpretation in apoptosis-centric models.

Recent thought-leadership on 'VX-765 and the Caspase-1 Frontier' highlights how VX-765 enables advanced modeling of IL-1β/IL-18 modulation and pyroptosis, whereas this article focuses on new specificity data and practical guidance for experimental design.

Common Pitfalls or Misconceptions

• VX-765 does not inhibit all caspases equally; its primary target is caspase-1, with moderate inhibition of caspase-8 only at higher concentrations (Bourne et al., 2025).
• VX-765 does not suppress the production or secretion of IL-6, IL-8, TNFα, or IL-α, so it is not a pan-cytokine inhibitor (ApexBio).
• VX-765 is insoluble in water; using inappropriate solvents may reduce experimental efficacy (ApexBio datasheet).
• Long-term or high-temperature storage of VX-765 solutions can lead to degradation; only prepare solutions for short-term use and store desiccated at -20°C (ApexBio).
• Assay conditions (e.g., pH, buffer composition) can influence VX-765 potency; standardize conditions for reproducibility.

Workflow Integration & Parameters

VX-765 is formulated as a solid and should be dissolved in DMSO (≥313 mg/mL) or ethanol (≥50.5 mg/mL with ultrasonic) just prior to use. It is insoluble in water. Solutions should be freshly prepared and used within a short time frame. Store the solid compound desiccated at -20°C. Enzyme inhibition assays should be conducted in buffered conditions at pH 7.5 with enzyme stabilizers as recommended. For in vivo studies, oral administration is standard, leveraging the compound's prodrug nature for metabolic conversion to VRT-043198. In cell-based models, dose titration is essential to balance selectivity and minimize off-target effects (notably against caspase-8). For a detailed protocol comparison, 'VX-765: A Selective Caspase-1 Inhibitor Empowering Inflam...' provides application-specific workflows, while this article updates with new specificity and storage guidance.

Conclusion & Outlook

VX-765 remains a benchmark tool for dissecting caspase-1-mediated inflammation, with validated selectivity for IL-1β and IL-18 modulation and a robust profile in diverse preclinical models. Its moderate off-target activity at high concentrations underscores the importance of dose optimization. Ongoing research is expanding VX-765's utility to neurological and autoimmune disease models. For further mechanistic insights into pyroptosis and caspase-1 pathway modulation, see 'VX-765: Next-Generation Caspase-1 Inhibition in Pyroptosi...', which extends the discussion to apoptotic cross-talk and future therapeutic development. For direct product specifications and ordering, refer to the VX-765 (A8238) product page.